Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Transcode Therapeutics, Inc.

NASDAQ: RNAZ · Life Sciences · 4 alerts · CIK 1829635

Share price
$1.35Close, Nov 16
Market cap
$23.4M
Shares outstanding
17.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Transcode Therapeutics, Inc. filings on SEC EDGAR ↗

4:36 PM ET 8-K
Other 8-K Filing

Transcode Therapeutics Other 8-K Filing

TransCode Therapeutics has initiated a formal strategic process to evaluate alternatives for maximizing the value of its oncology portfolio, including its lead Phase 2a candidate TTX-MC138. The company has engaged Tungsten Advisors to explore potential licensing deals, development partnerships, asset sales, or business combinations.

Counterparty
Tungsten Advisors
4:06 PM ET 8-K
Loan & Debt

Transcode Therapeutics $841K Debt Financing with YA II PN, Ltd.

TransCode Therapeutics made a $840,975 prepayment to Yorkville to resolve a potential 'Amortization Event' triggered by its stock price falling below a $1.72 floor price. In exchange for the payment, which includes $759,000 in principal plus premiums and interest, Yorkville waived the amortization requirement through October 31, 2026. Approximately $4.1 million in principal remains outstanding under the convertible notes.

Value
$841K
Counterparty
YA II PN, Ltd. (Yorkville)
8:17 AM ET 8-K
Clinical Trial Data

Transcode Therapeutics Clinical Trial Data

TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.

9:09 AM ET 8-K
Leadership Change

Transcode Therapeutics Leadership Change

Thomas A. Fitzgerald resigned as CFO and Director of TransCode Therapeutics effective September 9, 2026. The company entered into a separation agreement providing for up to $1.25 million in severance payments, accelerated vesting of existing equity, and a new grant of 185,000 stock options. A portion of the cash severance and option vesting is contingent on the company achieving specific funding thresholds of $5 million and $10 million.

Counterparty
Thomas A. Fitzgerald
Term
12 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.